This fits our experience with the parental Panc02 tumor model, since while it is unresponsive to T cell targeted therapies as discussed above, it has proven responsive to radiation therapy combined with therapies targeting myeloid populations in the tumor environment, including therapies targeting NFkB p50, Mertk, TGFb, and STING (199–201). The gene discussed is MERTK; the disease is neoplasm.